华东师范大学生命科学学院卢伟强研究员和刘明耀教授团队合作，在 Nature Immunology 期刊发表了题为： The lactate receptor HCAR1 drives the recruitment of ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. | The rising class of bispecifics ...

Programmed death I (PD-1), an inhibitory receptor on immune system cells, has long been known to play an important dual role in immune regulation: Preventing the immune system from attacking the self ...

PD-1 is a cell-surface receptor that resides on T and B cells, keeping immune cells from attacking other cells within the body. This prevents autoimmune diseases but also prevents the immune system ...

"programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments. A "checkpoint" receptor that often resides on the surface of immune system cells, the PD-1 ...

A 3-D image shows a T cell expressing the immune checkpoint receptor PD-1 (green) interacting with an antigen presenting cell expressing the ligand PD-L1 (magenta).

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The PD-1 protein functions as a type of off switch that prevents immune cells from attacking other cells. It is a “checkpoint” receptor that frequently appears on the surface of immune system ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...